Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Staphylococcus aureus is a significant pathogen, with increasing resistance to antibiotics like methicillin (MRSA) and vancomycin.
• Emerging vancomycin resistance, including heteroresistant vancomycin-intermediate S. aureus (hVISA) and vancomycin-intermediate S. aureus (VISA), complicates treatment.
• VISA and hVISA infections are linked to poor clinical outcomes and treatment failures.

Purpose of the Study:

• To provide an evidence-based review of S. aureus isolates exhibiting reduced susceptibility to vancomycin.
• To elucidate the prevalence, mechanisms of resistance, clinical significance, and detection methods for hVISA and VISA.
• To address the uncertainties hindering the clinical application of research findings on vancomycin-resistant S. aureus.

Main Methods:

• Literature review of scientific articles and clinical studies.
• Analysis of data on S. aureus resistance patterns.
• Synthesis of information on hVISA and VISA prevalence and detection.

Main Results:

• Increasing reports of S. aureus heteroresistance to vancomycin are noted.
• hVISA and VISA infections present complex clinical challenges.
• Current understanding of hVISA/VISA prevalence, mechanisms, and detection remains inconclusive.

Conclusions:

• Vancomycin's efficacy is challenged by rising S. aureus resistance.
• Further research is needed to clarify the clinical impact and management of hVISA and VISA.
• Standardized detection and treatment guidelines for vancomycin-resistant S. aureus are necessary.